The prevalence of GATA2 deficiency is currently unknown, but given the significant disease penetrance and low tolerance to pathogenic mutations in the GATA2 gene, it is likely that most carriers of the mutation will develop hematologic or immunologic complications over the course of their lifetime. This evidence concerns the gene GATA2 and hyperinsulinemic hypoglycemia, familial, 4.